Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded by The Goldman Sachs Group to Strong-Buy Rating

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by research analysts at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

Other analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 target price for the company. Guggenheim assumed coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price target for the company. Leerink Partners initiated coverage on Latigo Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and an average target price of $52.25.

Latigo Biotherapeutics Price Performance

Shares of Latigo Biotherapeutics stock opened at $22.26 on Tuesday. Latigo Biotherapeutics has a 12-month low of $17.22 and a 12-month high of $25.93.

Insider Activity at Latigo Biotherapeutics

In other news, Director James B. Tananbaum bought 140,000 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.